Teva Reports Q3 Results Today After a Strong Run-Up

TEVA releases its third-quarter results today, November 4, with the stock at $41.91 after gaining 6% over the past month and roughly 4% in the past week. The options market spent the last few days of October in decidedly call-heavy territory, though the put/call ratio has edged back toward its 20-day average of 0.51, sitting at 0.51 at Monday's close. That is a marked shift from the lopsided call positioning documented earlier in the week, when the ratio was pushing toward the bottom of its 52-week range near 0.44. The borrowing market remains loose in every measurable way: availability is around 1,128% of short interest, borrow costs are 0.48%, and an estimated 29.6 million shares are short, down from above 36 million in early October.

The fundamental debate is straightforward for a company still carrying heavy legacy debt while executing a biosimilars and specialty-pharma rebuild. At roughly 14x trailing earnings and an EV/EBITDA of 11.7x, both multiples have expanded modestly over the past month as the stock climbed, suggesting the market is willing to pay more for the turnaround story than it was a quarter ago. The earnings yield ranks in the 85th percentile relative to the broader universe, a signal that at current prices the stock still screens as reasonably valued by that measure. Bears have focused on the pace of debt reduction and pricing pressure in generics. The bull case rests on biosimilar pipeline progress and the operational leverage that comes from getting the balance sheet lighter. Neither side has dramatically shifted the short book: estimated short interest is down 15% over the past month, a steady retreat rather than a capitulation.

BlackRock holds 8.4% of shares as of September 30, adding nearly 28 million shares in the most recent reported period. That is the most significant institutional move on the register and reflects a material conviction bet from the world's largest asset manager. WCM Investment Management and Vanguard Capital Management also added modestly in the same quarter. The Israeli institutional ownership cluster, Phoenix, Harel, Clal, Migdal and Menora, collectively holds above 20% of shares, giving the register a distinctive domestic-anchor character that differentiates Teva from most large-cap US pharma names.

One data point from outside the financial markets is worth noting. ORTEX's Wikipedia views dataset, published by the Wikimedia Foundation, showed retail attention to Teva running at a z-score of 3.65 relative to its own 90-day history as of October 20. That is an unusually high spike in public interest ahead of a results day. The dataset has not been measured or tested as a lead indicator for Teva's reported figures, so it carries no forecasting weight. It does, however, suggest the Q3 print is drawing broader attention than a typical quarterly release for the company.

The report today will test whether Teva's operational progress in biosimilars and specialty drugs is translating into the kind of margin improvement that justifies the multiple expansion of recent weeks, and whether the debt trajectory is moving fast enough to satisfy investors who have watched the stock more than double from its 2024 lows.